Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03301363
Other study ID # SCOPE-CRT IRCCSDonato
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 30, 2017
Est. completion date December 31, 2023

Study information

Verified date September 2023
Source IRCCS Policlinico S. Donato
Contact Vincenzo Santinelli, MD
Phone +39 0252774260
Email vincenzo.santinelli@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to compare electrical acute changes between simultaneous and sequential LV pacing and to assess the paced QRSd over a range of inter- and intra-ventricular programmable delays setting during MPP pacing.


Description:

The study will be a prospective, single-arm, non-randomized, non-blinded, acute study conducted at CRT device implant and prior to subject discharge. Subjects scheduled to be implanted with a Quadripolar Pacing System who provide informed consent will undergo "Enrollment" and participate in "SCOPE-CRT" study. Enrollment and device implant can occur in the same day. Including Enrollment, each subject's participation is expected to be 1-2 days. The total duration of the study is expected to be 12 months, including Enrollment. Enrollment will include the Informed Consent process, physical examination, and collection of demographics, cardiovascular history, medical history, and medications. During CRT implant, surface ECG and PV loop recordings will be taken over the different programmable MPP settings. Following data collection, CRT device programming will be left to the discretion of the physician.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 31, 2023
Est. primary completion date September 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with approved indication for CRT by European Society of Cardiology/European Heart Rhythm Association guidelines (ESC/EHRA) - QRS duration > 130 ms - Ability to provide informed consent for study participation - At least 18 years of age Exclusion Criteria: - Myocardial infarction within 40 days before enrolment - NYHA Class IV - Tachyarrhythmia caused by temporary or reversible irritation, e.g. poisoning, electrolyte imbalance, hypoxia, sepsis or acute myocardial infarction - Such frequent VT or VF that the therapies would cause an unacceptably rapid depletion of the device batteries - VT with few or without clinically relevant symptoms - VT or VF treatable by surgery - Concomitant diseases that would substantially limit a positive prognosis - Accelerated intrinsic rhythm - Women who are pregnant

Study Design


Related Conditions & MeSH terms

  • Cardiac Resynchronization Therapy

Intervention

Device:
CRT
Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System

Locations

Country Name City State
Italy IRCCS Policlinico S. Donato San Donato Milanese Milano

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Donato

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute QRS duration changes during multipoint CRT Quantify acute changes in surface ECG QRS duration between simultaneous and sequential LV pacing during MPP pacing. 1 day during CRT
Secondary Acute ECG QRS duration changes during multipoint CRT Quantify acute changes in surface ECG QRSd over a range of inter- and intra-ventricular programmable delays setting during multipoint CRT pacing.
•
1 day during CRT
Secondary Acute changes in hemodynamics between simultaneous and sequential LV pacing during multipoint CRT Quantify acute changes in hemodynamics between simultaneous and sequential LV pacing during multipoint CRT pacing over a range of inter- and intra-ventricular programmable delays settings. 1 day during CRT
See also
  Status Clinical Trial Phase
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Recruiting NCT01515761 - POsition of Leads in Advanced heaRt Failure: the POLAR Study N/A
Completed NCT04595305 - Septal Mapping And Resynchronisation Therapy- (SMART) Study N/A
Not yet recruiting NCT05985408 - LVSP Based CRT vs. RVAP Based CRT N/A
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Completed NCT04505384 - Acute Effects of LBBP Versus BVP for CRT N/A
Suspended NCT04347109 - cArdiac Non Invasive MApping in resynchronizaTION
Recruiting NCT02962791 - Prospective Randomized Trial Comparing TRIPLE Site ventriculAr Stimulation Versus Conventional Pacing in CRT canDidates N/A
Recruiting NCT03587064 - Comparison of CRT-D and CRT-DX Systems (CRT-NEXT) N/A
Recruiting NCT06105580 - Conduction System Pacing vs Biventricular Pacing in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant N/A
Recruiting NCT03415945 - Left Ventricular Septal Pacing: Potential Application for Cardiac Resynchronization Therapy N/A
Completed NCT04299360 - Comparison of Multi-point Pacing and Conventional CRT Through Non-invasive Hemodynamics Measurement and Global Longitudinal Strain Assessment
Suspended NCT02728336 - MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT) N/A
Completed NCT00395642 - TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D Phase 4
Completed NCT03367104 - Narrow QRS HF Patients Assessed by ECG Belt
Recruiting NCT05971225 - Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) N/A
Terminated NCT04870281 - Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System
Recruiting NCT05327062 - Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment N/A
Completed NCT01850264 - Quartetâ„¢ Bad Oeynhausen Trial N/A
Terminated NCT04600921 - Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study Phase 3